LianBio reports FY2022 net loss of $110.3M; cash $302.4M with runway through end of 2024

LianBio

Net loss $18.3M in Q4 2022 ($21.2M in Q4 2021); FY2022 loss $110.3M vs $196.3M in 2021.
Cash, cash equivalents and marketable securities $302.4M at Dec 31, 2022, down $100.8M from 2021.
Phase 3 EXPLORER-CN trial of mavacamten completed patient visits; topline data expected mid-2023.
Entered commercial agreement with Pfizer for sisunatovir; received $20M upfront, eligible for up to $135M milestones.
Phase 3 LIBRA trial of TP-03 for Demodex blepharitis ongoing; data expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LianBio reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 27, 2023, LianBio issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-23-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.